



PTO/SB/21 (09-04)

IFW

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/678,639
Filing Date	October 3, 2003
First Named Inventor	He, Biao
Art Unit	1642
Examiner Name	Not yet assigned
Attorney Docket Number	023070-125630US

ENCLOSURES (Check all that apply)

- | | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement with PTO/SB/08A and PTO/SB/08B

<input type="checkbox"/> Certified Copy of Priority Document(s)

<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Cited References AA-BF; Return Postcard |
|--|---|--|

Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
---------	--


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Jean M. Lockyer, Ph.D.		
Date	1/6/05	Reg. No.	54,111

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Anna C. Kundel	Date	01/06/2005



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 023070-125630US
Client Reference No.: SF 2002-071-2

On January 6, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HE et al.

Application No.: 10/678,639

Filed: October 3, 2003

For: METHODS FOR TREATING
CANCER BY INHIBITING WNT
SIGNALING

Examiner: Not yet assigned

Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jean M. Lockyer, Ph.D.
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:ack
60389118 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/678,639	
			Filing Date	October 3, 2003	
			First Named Inventor	He, Biao	
			Art Unit	1642	
			Examiner Name	Not yet assigned	
Sheet	2	of	3	Attorney Docket Number	023070-125630US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AD	APPEL, J., et al., "Elucidation of Discontinuous Linear Determinants in Peptides," <u>The Journal of Immunology</u> , February 1990, pp. 976-983, Vol. 144, USA.	
	AE	BIENZ et al., "Linking Colorectal Cancer to Wnt Signaling," <u>Cell</u> , 2000, pp. 311-320, Vol. 103, Cell Press	
	AF	BROWN et al., "Wnt signaling in breast cancer: have we come full circle?" <u>Breast Cancer Res.</u> 2001, pp. 351-355, Vol. 3	
	AG	CHEN et al., "Wnt-1 Signaling Inhibits Apoptosis by Activating β -Catenin/T Cell Factor-mediated Transcription," <u>J Cell Biol.</u> 2001, pp. 87-96, Vol. 152, No. 1, The Rockefeller University Press.	
	AH	COX et al., "A Screen for Mutations That Suppress the Phenotype of <i>Drosophila armadillo</i> , the β -Catenin Homolog," <u>Genetics</u> , 2000, pp. 1725-1740, Vol. 155.	
	AI	DE LA COSTE et al., "Somatic mutations of the β -catenin gene are frequent in mouse and human hepatocellular carcinomas," <u>Proc Natl Acad Sci USA</u> , 1998, pp. 8847-8851, Vol. 95.	
	AJ	FEDI et al., "Isolation and Biochemical Characterization of the Human Dkk-1 Homologue, a Novel Inhibitor of Mammalian Wnt Signaling," <u>J Biol Chem</u> , 1999, pp. 19465-19472, Vol. 274, No. 27.	
	AK	FINCH, P., "Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action," <u>Proc. Natl. Acad. Sci. USA</u> , June 1997, pp. 6770-6775, Vol. 94.	
	AL	HE et al., "Identification of c-MYC as a Target of the APC Pathway," <u>Science</u> , 1998, pp. 1509-1512, Vol. 281.	
	AM	IOANNIDIS et al., "The β -catenin-TCF-1 pathway ensures CD4 ⁺ CD8 ⁺ thymocyte survival," <u>Nat Immunol</u> , 2001, pp.691-697, Vol. 2, No. 8.	
	AN	KATOH, et al., "WNT2B2 mRNA, Up-Regulated in Primary Gastric Cancer, Is a Positive Regulator of the WNT- β -Catenin-TCF Signaling Pathway," <u>Biochemical and Biophysical Research Communications</u> , 2001, pp. 1093-1098, Vol. 289, Elsevier Science.	
	AO	LACHER, M., et al., "Wnt-Frizzled signaling in cell proliferation and survival," <u>Nature</u> , 2001, 1 page, abstract only, [33]	
	AP	MATSUZAWA et al., "Siah-1, SIP, and Ebi Collaborate in a Novel Pathway for β -Catenin Degradation Linked to p53 Responses," <u>Mol Cell</u> , 2001, pp. 915-926, Vol. 7, Cell Press.	
	AQ	MELKONYAN et al., "SARPs: A family of secreted apoptosis-related proteins," <u>Proc Natl Acad Sci USA</u> , 1997, pp. 13636-13641, Vol. 94.	
	AR	MILLER et al., "Mechanism and function of signal transduction by the Wnt/ β -catenin and Wnt/ Ca^{2+} pathways," <u>Oncogene</u> , 1999, pp. 7860-7872, No. 18, Stockton Press	
	AS	MOON et al., "Structurally Related Receptors and Antagonists Compete for Secreted Wnt Ligands," <u>Cell</u> , March 1997, pp. 725-728, Vol. 88, Cell Press.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/678,639	
			Filing Date	October 3, 2003	
			First Named Inventor	He, Biao	
			Art Unit	1642	
			Examiner Name	Not yet assigned	
Sheet	3	of	3	Attorney Docket Number	023070-125630US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AT	NUSSE et al., "Making head or tail of Dickkopf," <u>Nature</u> , 2001, pp. 255-256, Vol. 411.	
	AU	ORFORD et al., "Exogenous Expression of β -Catenin Regulates Contact Inhibition, Anchorage-independent Growth, Anoikis, and Radiation-induced Cell Cycle Arrest," <u>J Cell Biol</u> , 1999, pp. 855-868, Vol. 146.	
	AV	POLAKIS et al., "Wnt signaling and cancer," <u>Genes Dev</u> , 2000, pp. 1837-1851, Vol. 14, Cold Spring Harbor Laboratory Press.	
	AW	RHEE, C-S., et al., "Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas," <u>Oncogene</u> , 2002, pp. 6598-6605, Vol. 21, Nature Publishing Group.	
	AX	REYA et al., "Wnt Signaling Regulates B Lymphocyte Proliferation through a LEF-1 Dependent Mechanism," <u>Immunity</u> , 2000, pp. 15-24, Vol. 13, Cell Press.	
	AY	SATOH et al., "AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1," <u>Nat Genet</u> , 2000, pp. 245-250, Vol. 24.	
	AZ	SHIN et al., "Intermolecular and Interdomain Interactions of a Dynamin-related GTP-binding Protein, Dnm1p/Vps1p-like Protein," <u>Journal of Biological Chemistry</u> , 1999, pp. 2780-2785 Vol. 274, USA.	
	BA	SHOU et al., "Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA," <u>Oncogene</u> , 2002, pp. 878-889, Vol. 21, Nature Publishing Group.	
	BB	SUZUKI et al., "A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer," <u>Nat Genet</u> , 2002, pp. 141-149, Vol. 31.	
	BC	TAIPALE, J., et al., "The Hedgehog and Wnt signaling pathways in cancer," <u>Nature</u> , May 2001, pp. 349-354, Vol. 411, Macmillan Magazines Ltd.	
	BD	TICE, D., et al., "Synergistic Induction of Tumor Antigens by Wnt-1 Signaling and Retinoic Acid Revealed by Gene Expression Profiling," <u>The Journal of Biological Chemistry</u> , April 2002, pp. 14329-35, Vol. 277, No. 16, USA.	
	BE	YOU et al., "Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis," <u>J Cell Biol</u> , 2002, pp. 429-440, Vol. 157, The Rockefeller University Press.	
	BF	UTHOFF et al., "Wingless-Type Frizzled Protein Receptor Signaling and Its Putative Role in Human Colon Cancer," <u>Mol Carcinog</u> , 2001, pp. 56-62, Vol. 31, Wiley-Liss, Inc.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.